Summary & Overview
Hip Replacement with Principal Diagnosis of Hip Fracture with MCC: Inpatient Reimbursement Overview
DRG 521 covers hip replacement or repair admissions with a principal diagnosis of hip fracture when a Major Complication or Comorbidity is present, capturing higher-acuity surgical and medical needs. This matters for inpatient reimbursement because assignment to this Diagnosis-Related Group typically results in higher Medicare payments to account for increased resource intensity and length of stay.
DRG 521 Overview
DRG 521 (Hip Replacement with Principal Diagnosis of Hip Fracture with Major Complication or Comorbidity) groups inpatient admissions for patients undergoing hip replacement or repair when the principal diagnosis is a hip fracture and at least one Major Complication or Comorbidity is present. This Diagnosis-Related Group captures higher-acuity cases with greater resource use due to medical complexity, surgical complications, or significant comorbid conditions. It matters for Medicare payment because cases assigned to this Diagnosis-Related Group generally receive higher reimbursement to reflect increased hospital length of stay, use of intensive services, and post-operative management needs. Accurate clinical documentation and coding determine assignment to this Diagnosis-Related Group and therefore affect inpatient reimbursement.
Clinical Trials
- Acute surgical timing and perioperative optimization studies: randomized or prospective cohort studies examine the impact of time-to-surgery, anesthetic technique, and standardized perioperative bundles (eg, blood management, delirium prevention, early mobilization protocols) on short-term outcomes in elderly patients admitted for hip fracture who undergo hip arthroplasty with major complications or comorbidities. These trials focus on frail, often multimorbid older adults with hip fracture and MCCs (eg, cardiovascular disease, chronic kidney disease), assessing metrics such as in-hospital mortality, complication rates, length of stay, and need for intensive care. Findings inform hospital clinical pathways and resource planning for high-acuity DRG 521 cases and are directly relevant to payers because they affect episode costs, readmission risk, and downstream utilization.
- Comparative effectiveness studies of implant choice and surgical approach in complex hip fracture arthroplasty: observational registries and pragmatic randomized studies compare cemented versus cementless fixation, hemiarthroplasty versus total hip arthroplasty, and posterior versus anterolateral approaches specifically in patients whose hip fracture presentation is complicated by major comorbidities or intraoperative instability. The population includes older adults with high physiologic risk (MCC), and outcomes measured include implant survival, perioperative complications, functional recovery, and discharge disposition to home versus post-acute care. Results help surgeons and hospitals choose strategies that balance durable functional outcomes against perioperative risk and costs, guiding payer coverage policies and bundle payment designs for this high-cost DRG.
- Post-discharge recovery, rehabilitation, and health services research: longitudinal cohort studies and pragmatic trials evaluate intensity, timing, and setting of rehabilitation (inpatient rehab, skilled nursing facility, home-based therapy) and care coordination interventions for patients after hip replacement for fracture with MCCs, tracking functional status, quality of life, readmissions, and total 30- to 90-day episode costs. These studies target the frail elderly with complex medical needs to identify which post-acute pathways reduce complications such as medical decompensation or infection and improve return to baseline mobility. Evidence from this research is critical for providers optimizing discharge planning and for payers assessing the most cost-effective post-acute care models and risk adjustment for DRG 521 episodes.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.